Dr. Gilbert Tang/X
Nov 13, 2025, 01:15
Dr. Gilbert Tang Shares NEJM Late-Breaker: 7-Year Outcomes Reinforce TAVR as a Durable Option for Low-Risk Aortic Stenosis
Dr. Gilbert Tang, Vice Chair of Innovation, Cardiovascular Surgery Surgical and Academic Director at Mount Sinai Health System, shared a post on X:
“TCT2025 Late breaker PARTNER 3 Low Risk 7 Year Sapien3 TAVR vs SAVR showed no significant differences in composite endpoint, all-cause mortality, CV mortality, and low reintervention rates in both arms. Clinical valve thrombosis 2.8% TAVR vs 0.5% SAVR but similar BVF (valve failure) and reintervention.
Paper now online The New England Journal of Medicine (NEJM)
and can download here.
Nice TCTMD article.”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025